Acumen Pharmaceuticals Says First Patient Dosed In ALTITUDE-AD, A Phase 2 Clinical Trial Of Sabirnetug In Early Alzheimer's Disease
Acumen Pharmaceuticals Says First Patient Dosed In ALTITUDE-AD, A Phase 2 Clinical Trial Of Sabirnetug In Early Alzheimer's Disease
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.
Acumen Pharmicals, Inc.（納斯達克股票代碼：ABOS）是一家處於臨床階段的生物製藥公司，該公司正在開發一種針對毒性可溶性β澱粉樣低聚物（AβOS）的新療法，用於治療阿爾茨海默氏病（AD），今天宣佈，在旨在評估阿爾茨海默氏病臨床療效和安全性的ALTITUDE-AD 2期臨床試驗中，第一位患者服用了sabirnetug（ACU193）。對早期 AD 患者使用 sabirnetug。
"Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the forefront of the next generation of Alzheimer's therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug's therapeutic potential and a strong start to the trial."
Acumen首席執行官丹尼爾·奧康奈爾表示：“今天對Acumen和阿爾茨海默氏症社區來說是一個重要的里程碑，因爲我們開始了sabirnetug的2期試驗。”“Sabirnetug處於下一代阿爾茨海默氏症療法的最前沿，令人鼓舞的1期結果支持其對毒性β澱粉樣低聚物的新作用機制和選擇性。這些結果使研究人員和患者對sabirnetug的治療潛力產生了濃厚的興趣，也爲該試驗開了一個良好的開端。”
譯文內容由第三人軟體翻譯。